JENNEREX BIOTHERAPEUTICS
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.
JENNEREX BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2003-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.jennerex.com
Total Employee:
11+
Status:
Active
Contact:
14155982600
Email Addresses:
[email protected]
Total Funding:
56.05 M USD
Technology used in webpage:
Domain Not Resolving Apache GoDaddy DNS Sectigo SSL Sectigo Domain SSL GoDaddy Premium DNS Bizland
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Oncolix
Oncolix is a clinical-stage bio-pharmaceutical company developing a therapeutic protein for the treatment of cancer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ottawa Regional Cancer Foundation
Ottawa Regional Cancer Foundation investment in Series C - Jennerex Biotherapeutics
More informations about "Jennerex Biotherapeutics"
Jennerex - Wikipedia
Jennerex Biotherapeutics, Inc. (now owned by SillaJen) was an American private biopharmaceutical company [1] [3] that developed the oncolytic viruses JX-594 [1] [4] and JX โฆSee details»
Jennerex Biotherapeutics - Crunchbase Company โฆ
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted โฆSee details»
Jennerex | SILLAJEN
Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply to tumors, and by activating โฆSee details»
Jennerex Biotherapeutics - 2025 Company Profile - Tracxn
Jennerex Biotherapeutics is an acquired company based in San Francisco (United States), founded in 2003 by David Kirn. It operates as a Develops Oncolytic viruses for cancer. โฆSee details»
Organization | Jennerex Inc.
Organization Overview. First Clinical Trial. 2008 NCT00629759. First Marketed Drug. None First NDA Approval. None ... Jennerex Biotherapeutics | Jennerex Biotherapeutics (Jennerex, Inc.) โฆSee details»
Jennerex, Inc. - San Francisco, USA - bionity.com
Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in โฆSee details»
Jennerex Biotherapeutics - PitchBook
Jennerex Biotherapeutics General Information Description. Developer of oncolytic products intended to treat cancer. The company provides an engineered oncolytic virus that selectively targets and destroys cancer cells and targets the โฆSee details»
Jennerex Biotherapeutics - Products, Competitors, Financials, โฆ
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. Use โฆSee details»
Jennerex Biotherapeutics Inc - Company Profile and News
Company profile page for Jennerex Biotherapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
SillaJen Announces Agreement to Acquire Jennerex, Inc.
Dec 2, 2013 Jennerex is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life โฆSee details»
EIN 26-1730046 - Jennerex, Inc., San Francisco, California
Jennerex, Inc. is a corporation in San Francisco, California. The employer identification number (EIN) for Jennerex, Inc. is 261730046. EIN for organizations is sometimes also referred to as โฆSee details»
Korea's SillaJen to acquire Jennerex in up to $150 million deal
Nov 27, 2013 To this end, SillaJen says it is actively collaborating with Jennerex and its global partners on transition planning, including finalizing a robust clinical development plan. It โฆSee details»
Jennerex Biotherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
Jennerex and Transgene Enter Into an Exclusive Partnership for the
Sep 8, 2010 /CNW/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic...See details»
jennerex โ The Virus Project
Organizations; Media Resources; About. THE VIRUS PROJECT; About the Site; Virus Project Team; Altru Institute; Newsletters; Open Source Journalism ... August 15, 2009 0. Jennerex โฆSee details»
Jennerex Biotherapeutics | CipherBio
Explore Jennerex Biotherapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
What is Jennerex? Company Culture, Mission, Values
See what employees say it's like to work at Jennerex. Salaries, reviews, and more - all posted by employees working at Jennerex.See details»
Jennerex Completes $8.3 Million Series B Financing and Appoints โฆ
Sep 10, 2008 Advertisement Jennerex also announces the appointment of Calvin Stiller, CM, O. ONT, MD, F.R.C.P. (C) to the Company's Board of Directors. Dr. Stiller is Chairman of the โฆSee details»
Jennerex | ์ ๋ผ์
Jennerex๋ ํญ์๋ฐ์ด๋ฌ์ค ๋ถ์ผ์์ ์ด์ฐฝ๊ธฐ ์ ๊ตฌ์์์ต๋๋ค. Jennerex ์ฐ๊ตฌ์ง์ ์ํด ๊ท๋ช ๋ ํ์ฌ๋ฒก์ ์์ฉ๊ธฐ์ ์ ํ์ฌ๋ฒก ๊ฐ์ผ์ ์ํ ์์ธํฌ ์ง์ ์ด์, ์ํ๊ด ์ฐจ๋จ, ํ์์ ๋ฉด์ญ์ฒด๊ณ โฆSee details»
Jennerex Plucks $21.6M Private Placement; Is IPO Up Next?
May 24, 2013 Jennerex Biotherapeutics Inc. completed an insider-based $21.6 million private placement, capping a fruitful week that included the full enrollment of a Phase IIb study of โฆSee details»